Beta-lactamase inhibiting 6-beta-sulfonyloxypenicillanic acid derivatives
    4.
    发明授权
    Beta-lactamase inhibiting 6-beta-sulfonyloxypenicillanic acid derivatives 失效
    β-内酰胺酶抑制6-β-磺酰氧基青霉烷酸衍生物

    公开(公告)号:US4486411A

    公开(公告)日:1984-12-04

    申请号:US279404

    申请日:1981-07-01

    IPC分类号: A61K31/43 A61K35/00

    CPC分类号: A61K31/43

    摘要: 6-Beta-sulfonyloxypenicillanic acid derivatives are novel beta-lactamase inhibitors, useful in combination with standard beta-lactam antibiotics against bacterial strains otherwise resistant to said beta-lactam antibiotics by dint of their production of beta-lactamases.

    摘要翻译: 6-β-磺酰氧基青霉烷酸衍生物是新型β-内酰胺酶抑制剂,可与标准的β-内酰胺抗生素结合使用,对抗细菌菌株,通过其β-内酰胺酶的生产而对所述β-内酰胺抗生素具有抗性。

    Substituted heteroaryl- and phenylsulfamoyl compounds
    5.
    发明授权
    Substituted heteroaryl- and phenylsulfamoyl compounds 失效
    取代的杂芳基 - 和苯基氨磺酰基化合物

    公开(公告)号:US07262318B2

    公开(公告)日:2007-08-28

    申请号:US11012139

    申请日:2004-12-16

    IPC分类号: C07C321/00 A61K8/64 A01N65/00

    摘要: The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

    摘要翻译: 本发明涉及取代的杂芳基 - 和苯基氨磺酰基化合物,含有这些化合物的药物组合物以及这些化合物如过氧化物酶体增殖物激活受体(PPAR)激动剂的用途。 PPARα激活剂,含有这些化合物的药物组合物以及使用这些化合物来提高某些血浆脂质水平,包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平,如低密度脂蛋白胆固醇和甘油三酸酯,从而治疗 由哺乳动物(包括人类)中低密度脂蛋白胆固醇和/或高水平的低密度脂蛋白胆固醇和甘油三酯(如动脉粥样硬化和心血管疾病)而加剧。 该化合物也可用于治疗反能动物中的负能量平衡(NEB)和相关疾病。

    Mutual prodrugs of amlodipine and atorvastatin
    6.
    发明授权
    Mutual prodrugs of amlodipine and atorvastatin 失效
    氨氯地平和阿托伐他汀的前药

    公开(公告)号:US06486182B1

    公开(公告)日:2002-11-26

    申请号:US09577561

    申请日:2000-05-24

    IPC分类号: A61K314439

    摘要: This invention relates to mutual prodrugs of amlodipine and atorvastatin and to pharmaceutical compositions thereof. This invention also relates to methods of treating angina pectoris, atherosclerosis, and hypertension and hyperlipidemia in a mammal using those prodrugs and compositions. This invention also relates to methods of managing cardiac risk in a mammal, including humans, presenting with symptoms of cardiac risk by administering those prodrugs and compositions.

    摘要翻译: 本发明涉及氨氯地平和阿托伐他汀的联合前体药物及其药物组合物。 本发明还涉及使用这些前药和组合物治疗哺乳动物心绞痛,动脉粥样硬化,高血压和高脂血症的方法。 本发明还涉及通过施用那些前药和组合物来治疗患有心脏病风险的哺乳动物(包括人)的心脏风险的方法。

    Mutual salt of amlodipine and atorvastatin
    7.
    发明授权
    Mutual salt of amlodipine and atorvastatin 失效
    氨氯地平和阿托伐他汀的盐

    公开(公告)号:US06262092B1

    公开(公告)日:2001-07-17

    申请号:US09578204

    申请日:2000-05-24

    IPC分类号: A01N4340

    摘要: This invention relates to a mutual salt of amlodipine and atorvastatin, pharmaceutical compositions thereof and methods of treating angina pectoris, atherosclerosis and combined hypertension and hyperlipidemia in mammals with such a mutual salt and compositions. This invention also relates to methods of managing cardiac risk in a mammal presenting with symptoms of cardiac risk, including humans by administering such a mutual salt and compositions.

    摘要翻译: 本发明涉及氨氯地平和阿托伐他汀的相互盐,其药物组合物和哺乳动物用这种相互盐和组合物治疗心绞痛,动脉粥样硬化和组合高血压和高脂血症的方法。 本发明还涉及通过施用这种共同的盐和组合物来管理呈现心脏病风险的哺乳动物的心脏风险的方法,包括人类。